» Articles » PMID: 15545746

Family Communication About Positive BRCA1 and BRCA2 Genetic Test Results

Overview
Journal Genet Med
Publisher Elsevier
Specialty Genetics
Date 2004 Nov 17
PMID 15545746
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The identification of a BRCA1 or BRCA2 genetic mutation can provide important health information to individuals who receive this result, but it can also provide crucial cancer risk information to family members. Most of the research on communication of genetic test results has focused on first degree relatives. The purpose of this retrospective study was to examine the process of communicating a positive BRCA1 or BRCA2 genetic test result to male and female first, second, and third degree relatives.

Methods: Participants were 38 female mutation carriers who responded to a written survey assessing the number and relationship of relatives informed, methods used to inform relatives, topics discussed, and motivations and barriers for communication.

Results: Overall, 59% (470/803) of first, second, and third degree relatives were informed. The proportion of informed parents, siblings, and offspring was nearly twice that of more distant relatives including nieces, nephews, aunts, uncles, grandchildren, and cousins (88% versus 45%; P = 0.02). The method of communication differed by the gender of the relative, as did some of the topics discussed. The most important reasons for discussing the genetic test results were (1) to inform the relatives of their risk, (2) to suggest that they be tested, and (3) to fulfill a perceived duty to inform. The major barrier to communication was little contact and/or emotionally distant relationships.

Conclusion: Female mutation carriers act on a perceived duty to inform close relatives of their positive test result; however, there is a need for genetic counseling strategies that address communication with more distant relatives.

Citing Articles

Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.

Assad H, Levitin M, Petrucelli N, Manning M, Thompson H, Chen W Breast Cancer Res Treat. 2024; 206(2):261-272.

PMID: 38605155 DOI: 10.1007/s10549-024-07283-0.


Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs.

Levine R, Kahn R, Perez L, Brewer J, Ratner S, Li X Fam Cancer. 2024; 23(2):111-120.

PMID: 38530571 DOI: 10.1007/s10689-024-00373-4.


Do people with hereditary cancer syndromes inform their at-risk relatives? A systematic review and meta-analysis.

Ahsan M, Levi S, Webster E, Bergeron H, Lin J, Narayan P PEC Innov. 2023; 2:100138.

PMID: 37214514 PMC: 10194207. DOI: 10.1016/j.pecinn.2023.100138.


Young-onset colorectal cancer.

Spaander M, Zauber A, Syngal S, Blaser M, Sung J, You Y Nat Rev Dis Primers. 2023; 9(1):21.

PMID: 37105987 PMC: 10589420. DOI: 10.1038/s41572-023-00432-7.


Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.

Frey M, Ahsan M, Bergeron H, Lin J, Li X, Fowlkes R J Clin Oncol. 2022; 40(35):4129-4143.

PMID: 35960887 PMC: 9746789. DOI: 10.1200/JCO.22.00303.